CTOs on the Move

Id Labs Inc

www.idlabs.com

 
Id Labs Inc is a London, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.idlabs.com
  • PO Box 1145 Stn B
    London, ON CAN N6A 5K2
  • Phone: 519.434.5057

Executives

Name Title Contact Details

Similar Companies

Protea Biosciences

Protea Biosciences is a Morgantown, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

13Therapeutics Inc

13Therapeutics Inc is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoArendi Therapeutics

OncoArendi Therapeutics SA (WSE:OAT) is a Polish innovative biotechnology company specializing in research, development and commercialization of innovative small molecule drugs for treatment of respiratory diseases and cancer.

Resolve Biosciences

Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights based on the highest-resolution view of spatial biology. The platform features the company`s proprietary, highly multiplexed, single-molecule detection technology, which offers full spatial context at subcellular resolution, all in a fully automated workflow that preserves the sample tissue. The Molecular Cartography technology offers unparalleled sensitivity and specificity that helps scientists detect individual transcripts and rare signals to interpret fundamental biology and rapidly advance the understanding of complex biological questions in critical fields such as oncology, neuroscience, and infectious disease. The technology has been under development since 2016 and is currently available through Resolve Biosciences` commercial service laboratory. Resolve Biosciences is privately held and based in Monheim am Rhein, Germany, with a North American facility and laboratory in San Jose, Calif.

Novus Therapeutics

Novus Therapeutics, Inc. (NASDAQ: NVUS) is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease.